Emicizumab prophylaxis and health-related outcomes in persons with hemophilia a (PwHA) with inhibitors: HAVEN 1 study

被引：0
作者：
Oldenburg, J. [1 ]
Mahlangu, J. N. [2 ,3 ]
Bujan, W. [4 ]
Trask, P. C. [5 ]
von Mackensen, S. [6 ]
Callaghan, M. U. [7 ]
Young, G. [8 ]
Asikanius, E. [9 ]
Peyvandi, F. [10 ]
Santagostino, E. [10 ]
Kruse-Jarres, R. [11 ]
Negrier, C. [12 ]
Kessler, C. [13 ]
Levy, G. G. [14 ]
Windyga, J. [15 ]
Shima, M. [16 ]
机构：
[1] Univ Klinikum Bonn, Bonn, Germany
[2] Univ Witwatersrand, Fac Hlth Sci, Haemophilia Comprehens Care Ctr, Johannesburg, South Africa
[3] NHLS, Johannesburg, South Africa
[4] Inst Costarricense Invest Cient, San Jose, Costa Rica
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Univ Med Ctr Hambur Eppendorf, Dept Med Psychol, Hamburg, Germany
[7] Childrens Hosp Michigan, Detroit Med Ctr, Detroit, MI 48201 USA
[8] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA USA
[9] F Hoffmann La Roche Ltd, Basel, Switzerland
[10] Osped Maggiore Policlin, IRCCS Ca Granda Fdn, Milan, Italy
[11] Univ Washington, Washington Ctr Bleeding Disorders BloodWorks NW, Seattle, WA 98195 USA
[12] Univ Claude Bernard, Louis Pradel Cardiol Hosp, Lyon, France
[13] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[14] Genentech Inc, Pharma Dev Oncol, San Francisco, CA 94080 USA
[15] Inst Hematol & Transfus Med, Warsaw, Poland
[16] Nara Med Univ, Dept Pediat, Kashihara, Nara, Japan
来源：
HAEMOPHILIA | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P120
引用
收藏
页码：89 / 90
页数：2
相关论文
共 50 条
  • [21] Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study
    Pipe, Steven
    Collins, Peter
    Dhalluin, Christophe
    Kenet, Gili
    Schmitt, Christophe
    Buri, Muriel
    Jimenez-Yuste, Victor
    Peyvandi, Flora
    Young, Guy
    Oldenburg, Johannes
    Mancuso, Maria Elisa
    Kavakli, Kaan
    Kiialainen, Anna
    Chang, Tiffany
    Lehle, Michaela
    Niggli, Markus
    Fijnvandraat, Karin
    BLOOD, 2023, 142
  • [22] Inhibitory Body Hemophilia A HAVEN-I Study demonstrates Efficacy of Bleeding Prophylaxis with Emicizumab
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2017, 44 (02) : 118 - 118
  • [23] Model of Short and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia.
    Mahajerin, Arash
    Zhou, Zheng-Yi
    Raimundo, Karina
    Patel, Anisha
    Han, Simeng
    Ji, Yusi
    Zhong, Jia
    Betts, Keith
    BLOOD, 2018, 132
  • [24] Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors
    Kempton, Christine
    Trask, Peter
    Parnes, Aric
    Niggli, Markus
    Campinha-Bacote, Avrita
    Callaghan, Michael U.
    O'Connell, Niamh
    Paz-Priel, Ido
    Mahlangu, Johnny N.
    HAEMOPHILIA, 2021, 27 (02) : 221 - 228
  • [25] HEALTH-RELATED QUALITY OF LIFE (HRQOL) IMPROVES IN PEOPLE WITH HEMOPHILIA A OR B (PWHA/B) WITH INHIBITORS RECEIVING FITUSIRAN PROPHYLAXIS: RESULTS OF PHASE 3 ATLAS-INH
    Negrier, C.
    Young, G.
    Sun, J.
    Wu, R.
    Qiu, Z.
    Andersson, S.
    Mei, B.
    Cano, V.
    Bartelt-Hofer, J.
    Srivastava, A.
    HAEMOPHILIA, 2022, 28 : 57 - 58
  • [26] Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
    Zhou, Zheng-Yi
    Raimundo, Karina
    Patel, Anisha M.
    Han, Simeng
    Ji, Yusi
    Fang, Honghao
    Zhong, Jia
    Betts, Keith A.
    Mahajerin, Arash
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (09) : 1109 - +
  • [27] Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study
    Pipe, Steven W.
    Collins, Peter
    Dhalluin, Christophe
    Kenet, Gili
    Schmitt, Christophe
    Buri, Muriel
    Jimenez-Yuste, Victor
    Peyvandi, Flora
    Young, Guy
    Oldenburg, Johannes
    Mancuso, Maria Elisa
    Kiialainen, Anna
    Chang, Tiffany
    Lehle, Michaela
    Fijnvandraat, Karin
    BLOOD, 2022, 140
  • [28] Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies (vol 137, pg 2231, 2021)
    不详
    BLOOD, 2023, 142 (15) : 1329 - 1329
  • [29] Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience
    Callaghan, Michael
    Trzaskoma, Benjamin
    Ko, Richard H.
    Lee, Lucy
    Patel, Anisha M.
    Tzeng, Eunice
    Shah, Michelle Lynn
    Chang, Tiffany Y.
    Niggli, Markus
    Dhalluin, Christophe
    Mahlangu, Johnny
    BLOOD, 2019, 134
  • [30] Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies
    Mahlangu, Johnny
    Jimenez-Yuste, Victor
    Ventriglia, Giuliana
    Niggli, Markus
    Barlera, Simona
    Hermans, Cedric
    Lehle, Michaela
    Chowdary, Pratima
    Jew, Lyle
    Windyga, Jerzy
    Frenzel, Laurent
    Schmitt, Christophe
    Castaman, Giancarlo
    Pipe, Steven W.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (02)
12345